Brown Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

Brown Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-84,989	Closed	-$1.33M	–	1251
2019 Q1	$1.33M	Buy	84,989 +35,061	+70%	+$618K	﹤0.01%	738
2018 Q4	$770K	Sell	49,928 -729	-1%	-$14.9K	﹤0.01%	813
2018 Q3	$1.09M	Buy	+50,657	New	+$1.18M	﹤0.01%	797
2017 Q4	–	Sell	-75,712	Closed	-$1.33M	–	1261
2017 Q3	$1.33M	Sell	75,712 -3,005,966	-98%	-$67.6M	﹤0.01%	602
2017 Q2	$102M	Buy	3,081,678 +514,280	+20%	+$15.9M	0.31%	70
2017 Q1	$82.4M	Sell	2,567,398 -639,120	-20%	-$21.8M	0.28%	78
2016 Q4	$116M	Sell	3,206,518 -253,986	-7%	-$10.1M	0.42%	59
2016 Q3	$159M	Sell	3,460,504 -23,642	-0.7%	-$1.23M	0.55%	49
2016 Q2	$175M	Buy	3,484,146 +363,968	+12%	+$19.4M	0.61%	41
2016 Q1	$167M	Sell	3,120,178 -116,495	-4%	-$6.84M	0.58%	43
2015 Q4	$212M	Buy	3,236,673 +140,802	+5%	+$8.7M	0.72%	38
2015 Q3	$175M	Buy	3,095,871 +274,289	+10%	+$17.8M	0.62%	41
2015 Q2	$167M	Sell	2,821,582 -14,186	-0.5%	-$875K	0.54%	43
2015 Q1	$177M	Sell	2,835,768 -53,553	-2%	-$3.11M	0.56%	41
2014 Q4	$166M	Buy	2,889,321 +25,825	+0.9%	+$1.44M	0.52%	43
2014 Q3	$154M	Buy	2,863,496 +289,152	+11%	+$15.3M	0.49%	44
2014 Q2	$135M	Sell	2,574,344 -22,748	-0.9%	-$1.16M	0.42%	43
2014 Q1	$137M	Buy	2,597,092 +2,579,018	+14,269%	+$119M	0.44%	40
2013 Q4	$725K	Buy	18,074 +2,350	+15%	+$92.5K	﹤0.01%	569
2013 Q3	$594K	Sell	15,724 -1,040	-6%	-$40.6K	﹤0.01%	592
2013 Q2	$657K	Buy	+16,764	New	+$653K	﹤0.01%	542

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Brown Advisory's TEVA Position: Q2 2019 in Review

Brown Advisory sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 84,989 shares — an estimated $1.33M sold.

Brown Advisory first reported a position in TEVA in Q2 2013 and held it in 21 quarters. The position peaked at $212M in Q4 2015. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

Brown Advisory reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Brown Advisory sold 84,989 Teva Pharmaceuticals shares in Q2 2019, an estimated $1.33M.
Brown Advisory first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 21 quarters.
Brown Advisory's Teva Pharmaceuticals position peaked at $212M in Q4 2015.
452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Brown Advisory's 13F filing for Q2 2019, filed 12 Aug 2019.